Zur Rose is said to have spoken to takeover companies
According to a Bloomberg report, the Swiss online pharmacy is currently weighing up several options. A sale has not been ruled out either.
The Swiss online pharmacy Zur Rose is reportedly Bloomberg report various strategic options, including possibly a sale. According to the report, the company has been in talks with potential buyers in recent months, including the US takeover firms KKR & Co and Hellman & Friedman, writes Bloomberg, citing people familiar with the matter.
Zur Rose declined to comment to Bloomberg. The company was founded in Switzerland in 1993 and initially only targeted doctors. In 2001, however, Zur Rose also began shipping medicines to doctors.
In 2017, the company, which also owns the Dutch mail-order pharmacy Docmorris, went public in Switzerland. In 2020, Zur Rose acquired the Munich-based start-up Teleclinic.
The share price of the Swiss online pharmacy has fallen by around 80 percent in the last twelve months. A few days ago, however, the share price received a brief boost when the company announced that it would break even by 2023 on the basis of adjusted earnings before interest, taxes, depreciation and amortization.
Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?
